Mergen Limited [1] announced it has resolved its patent infringement litigation case with Oxford Gene Technology [2]. Under the terms of the settlement, Mergen has obtained a license from OGT for its expression chips in the U.S., Europe and Japan. This license allows Mergen to manufacture and sell microarrays, e.g., Mergen’s ExpressChip(TM) DNA microarray system for high-throughput, high-sensitivity gene expression profiling. See the Press Release [3].